Get the Stockscreener App
0.5365
5.33%
-0.0235
Lexaria Bioscience Corp stock is traded at $0.5365, with a volume of 1.00M.
It is down -5.33% in the last 24 hours and down -52.67% over the past month.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
See More
Previous Close:
$0.56
Open:
$0.5471
24h Volume:
1.00M
Relative Volume:
1.24
Market Cap:
$13.19M
Revenue:
$411.00K
Net Income/Loss:
$-4.85M
P/E Ratio:
-1.2193
EPS:
-0.44
Net Cash Flow:
$-4.88M
1W Performance:
-9.00%
1M Performance:
-52.67%
6M Performance:
-38.33%
1Y Performance:
-77.63%
1-Day Range:
$0.46
$0.5471
1-Week Range:
$0.46
$0.6998
52-Week Range:
$0.46
$2.43
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Name
Lexaria Bioscience Corp
Sector
Industry
Phone
250-765-6424
Address
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
0.5302 | 13.94M | 411.00K | -4.85M | -4.88M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.70 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.77 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.18 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
846.33 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
178.10 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lexaria Bioscience Corp Stock (LEXX) Latest News
Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright - Investing.com
LEXX: HC Wainwright & Co. Lowers Price Target to $1.50, Maintains Buy Rating | LEXX Stock News - GuruFocus
LEXX: DehydraTECH Formulation Reduces GLP-1 Agonist Side Effects - Research Tree
Lexaria’s DehydraTECH-semaglutide cuts GLP-1 side effects in phase 1b trial and extends cash runway into 2026 - MSN
Primary Endpoint Successfully Achieved in Lexaria’s Phase 1b Study GLP-1-H24-4 - Hillsdale Daily News
Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus - Benzinga
Lexaria’s DehydraTECH-Semaglutide Cuts GLP-1 Side Effects in Phase 1b Trial and Extends Cash Runway Into 2026 - TipRanks
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 - Investing News Network
Is Lexaria Bioscience Corp. stock resilient to inflationJuly 2025 Market Mood & Weekly Consistent Profit Watchlists - Улправда
What momentum indicators show for Lexaria Bioscience Corp. stockPortfolio Growth Summary & AI Powered Market Trend Analysis - Улправда
Will Lexaria Bioscience Corp. stock deliver better than expected guidanceQuarterly Profit Review & Safe Capital Investment Plans - Улправда
Is Lexaria Bioscience Corp. stock a buy on dipsJuly 2025 Technicals & AI Optimized Trading Strategy Guides - Улправда
Lexaria Bioscience secures $3.5 million in direct offering to boost R&D - MSN
Portfolio Recap: What valuation multiples suggest for Lexaria Bioscience Corp. Equity Warrant stockBreakout Watch & Fast Entry and Exit Trade Plans - Улправда
Setup Watch: Is Lexaria Bioscience Corp. stock resilient to inflationSell Signal & Consistent Profit Trade Alerts - Улправда
How geopolitical tensions affect Lexaria Bioscience Corp. stockJuly 2025 Short Interest & Free Expert Verified Stock Movement Alerts - DonanımHaber
Will Lexaria Bioscience Corp. Equity Warrant stock benefit from AI adoptionWeekly Profit Summary & Risk Managed Trade Strategies - DonanımHaber
Published on: 2025-12-19 15:15:39 - DonanımHaber
Published on: 2025-12-19 14:32:21 - DonanımHaber
Is Lexaria Bioscience Corp. Equity Warrant stock trading at a premium valuationWeekly Earnings Recap & Weekly Top Stock Performers List - Улправда
Momentum Shift: Is Lexaria Bioscience Corp. Equity Warrant stock trading at a premium valuationJuly 2025 Breakouts & Daily Risk Controlled Trade Plans - Улправда
Lexaria Bioscience Corp. (LEXX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Lexaria Bioscience Secures $3.5 Million in Capital Through Registered Direct Offering - citybuzz -
Lexaria Bioscience closes $3.5 million registered direct offering - Investing.com
Lexaria Bioscience (NASDAQ: LEXX) details approximately $3.5 million financing terms - Stock Titan
Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Bluefield Daily Telegraph
Drug delivery company Lexaria raises $3.5M for R&D and working capital - Stock Titan
Lexaria Bioscience Corp. (NASDAQ: LEXX) offers 2,661,600 new shares of common stock - Stock Titan
Lexaria Bioscience plummets on $3.5M equity offering - MSN
Lexaria Bioscience raises $3.5 million in at-market offering By Investing.com - Investing.com Nigeria
Lexaria Bioscience raises $3.5 million in at-market offering - Investing.com India
Lexaria Bioscience Secures $3.5 Million in Direct Offering to Boost R&D - TipRanks
Lexaria Bioscience Corp. (LEXX) Drops 28% in Pre-market: Following Direct Offering Announcement - Stocks Telegraph
LEXX Appoints H.C. Wainwright & Co. as Exclusive Placement Agent - GuruFocus
Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Investing News Network
Lexaria Bioscience stock plunges after $3.5M at-the-market offering - Investing.com Canada
Lexaria (NASDAQ: LEXX) prices $3.5M direct stock offering, adds 5-year warrants - Stock Titan
Lexaria Bioscience (NASDAQ:LEXX) Downgraded by Wall Street Zen to “Sell” - Defense World
Lexaria Bioscience (Nasdaq: LEXX) updates prospectus for 314,287 warrant shares - Stock Titan
How Lexaria Bioscience Corp. Equity Warrant stock performs in high volatility markets2025 Support & Resistance & Intraday High Probability Setup Alerts - Newser
How Lexaria Bioscience Corp. Equity Warrant stock compares to growth peersJuly 2025 Setups & Verified Technical Signals - Newser
Is Lexaria Bioscience Corp. stock a safe haven assetTake Profit & Risk Adjusted Buy and Sell Alerts - Newser
Lexaria Bioscience (LEXX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Lexaria Bioscience Corp. (NASDAQ:LEXX): Are Analysts Optimistic? - Yahoo Finance
Lexaria Bioscience (NASDAQ:LEXX) Stock Rating Upgraded by Wall Street Zen - Defense World
Lexaria Bioscience Corp. SEC 10-K Report - TradingView
Lexaria Bioscience : Annual Report for Fiscal Year Ending 08-31, 2025 (Form 10-K) - marketscreener.com
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended - Investing News Network
Lexaria Bioscience Corp. Reports Earnings Results for the Full Year Ended August 31, 2025 - marketscreener.com
Lexaria Bioscience Corp Stock Analysis and ForecastVolatility Index Analysis & Unlock Long-Term Capital Growth Ideas - earlytimes.in
Lexaria Bioscience Corp Stock (LEXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
0.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):